×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

FTC BACKS DIRECT-TO-CONSUMER DRUG STUDY

By Published on .

WASHINGTON (AdAge.com) -- The Federal Trade Commission is urging the Food and Drug Administration to expand a planned study of the effects of direct-to-consumer drug advertising.

In comments filed with the Office of Management and Budget, the FTC said it supported the FDA's study, calling it "critical to our understanding of the role of advertising ... on consumer welfare."

The FTC also urged that the study include questions that could indicate whether the advertising is lowering the cost of drugs to consumers and how it is affecting insurance coverage.

In this article:
Most Popular